n Southern African Journal of HIV Medicine - Availability of Hivid - : letters

Volume 3, Issue 3
  • ISSN : 1608-9693
  • E-ISSN: 2078-6751



It has been brought to my attention that many HIV treating clinicians believe that zalcitabine (Hivid) has been taken off the market due to its related toxicities. I would like to dispel this perception and clearly state that Hivid is available and at no time has been taken off the market because of problems with toxicity. For your records, I enclose the corresponding journal references.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error